Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather Jacene

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2008
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumorsAntonio Jimeno, Michelle A Rudek, Peter Kulesza, et al.
Cancers|June 26, 2025
Race and Outcomes to [<sup>177</sup>Lu]Lu-PSMA-617 in Advanced Prostate CancerAvina Rami, Caiwei Zhong, Miguel Muniz, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 1, 2024
Joint EANM-SNMMI guidelines on the role of 2-[<sup>18</sup>F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelinesDavid Groheux, Sofia C Vaz, Gary A Ulaner, et al.
Breast (Edinburgh, Scotland)|September 20, 2024
Role of [<sup>18</sup>F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelinesDavid Groheux, Sofia C Vaz, Philip Poortmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2025
[<sup>18</sup>F]-Labeled Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Staging and Restaging Patients With Breast CancerDavid Groheux, Sofia C Vaz, Lioe-Fee de Geus-Oei, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2024
Joint EANM-SNMMI guideline on the role of 2-[<sup>18</sup>F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)Sofia C Vaz, John Patrick Pilkington Woll, Fatima Cardoso, et al.
Future Oncology (London, England)|October 6, 2025
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)Maeve A Hennessy, Constantine Gatsonis, Heather Jacene, et al.
The Prostate|March 19, 2025
Outcome of Subsequent Therapies After <sup>177</sup>Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center ExperienceMeryam Losee, Michael Kavanaugh, Mofei Liu, et al.
Blood Advances|March 4, 2020
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W Merryman, Natasha Edwin, Robert Redd, et al.
Blood|September 6, 2024
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphomaKatie Maurer, Isabella N Grabski, Roch Houot, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2008
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumorsAntonio Jimeno, Michelle A Rudek, Peter Kulesza, et al.
Cancers|June 26, 2025
Race and Outcomes to [<sup>177</sup>Lu]Lu-PSMA-617 in Advanced Prostate CancerAvina Rami, Caiwei Zhong, Miguel Muniz, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 1, 2024
Joint EANM-SNMMI guidelines on the role of 2-[<sup>18</sup>F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelinesDavid Groheux, Sofia C Vaz, Gary A Ulaner, et al.
Breast (Edinburgh, Scotland)|September 20, 2024
Role of [<sup>18</sup>F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelinesDavid Groheux, Sofia C Vaz, Philip Poortmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2025
[<sup>18</sup>F]-Labeled Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Staging and Restaging Patients With Breast CancerDavid Groheux, Sofia C Vaz, Lioe-Fee de Geus-Oei, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2024
Joint EANM-SNMMI guideline on the role of 2-[<sup>18</sup>F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)Sofia C Vaz, John Patrick Pilkington Woll, Fatima Cardoso, et al.
Future Oncology (London, England)|October 6, 2025
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)Maeve A Hennessy, Constantine Gatsonis, Heather Jacene, et al.
The Prostate|March 19, 2025
Outcome of Subsequent Therapies After <sup>177</sup>Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center ExperienceMeryam Losee, Michael Kavanaugh, Mofei Liu, et al.
Blood Advances|March 4, 2020
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W Merryman, Natasha Edwin, Robert Redd, et al.
Blood|September 6, 2024
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphomaKatie Maurer, Isabella N Grabski, Roch Houot, et al.
Pageof 7